Literature DB >> 12354856

Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma.

Satoshi Ogata1, Motoko Nagano-Fujii, Yonson Ku, Seitetsu Yoon, Hak Hotta.   

Abstract

The core protein of hepatitis C virus (HCV) has been implicated in hepatocarcinogenesis. In order to determine whether there is a correlation between mutations of the core protein and the development of hepatocellular carcinoma (HCC), the core protein-coding sequence of the viral genome of HCV subtype 1b (HCV-1b) obtained from patients with and without HCC was analyzed. We found that 12 (40.0%) of 30 HCV-1b isolates from patients with HCC but none of 29 isolates from patients without HCC had a point mutation(s) in an N-terminal region of 20 residues. Similarly, 10 (33.3%) of 30 isolates from patients with HCC had mutations in a limited region between residues 141 and 160, whereas only 2 (6.9%) of 29 isolates from patients without HCC did. The differences between the two groups were statistically significant. The mutations were found in isolates from both cancerous and adjacent noncancerous tissues of patients with HCC, suggesting that the mutations were present before the development of HCC. The other regions of the core protein of some isolates also had mutations, but no significant difference was observed between isolates from patients with HCC and those from patients without HCC. The F protein, a frameshift product that is still hypothetical for HCV-1b strains, showed more sequence diversity than the core protein among the isolates analyzed, but there were no significant differences in the mutation rates or positions between isolates from patients with HCC and isolates from patients without HCC, except for a short N-terminal sequence of approximately 11 residues that is shared with the core protein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354856      PMCID: PMC130847          DOI: 10.1128/JCM.40.10.3625-3630.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

Review 1.  Hepatitis C virus infection.

Authors:  G M Lauer; B D Walker
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

2.  A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia.

Authors:  J Hayashi; N Furusyo; I Ariyama; Y Sawayama; Y Etoh; S Kashiwagi
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

3.  Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1.

Authors:  H Aoki; J Hayashi; M Moriyama; Y Arakawa; O Hino
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

Authors:  N Kato; M Hijikata; Y Ootsuyama; M Nakagawa; S Ohkoshi; T Sugimura; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.

Authors:  J B Nousbaum; S Pol; B Nalpas; P Landais; P Berthelot; C Bréchot
Journal:  Ann Intern Med       Date:  1995-02-01       Impact factor: 25.391

6.  Analysis of hepatitis C virus isolates among healthy blood donors and drug addicts in Chiang Mai, Thailand.

Authors:  C Apichartpiyakul; C Chittivudikarn; H Miyajima; M Homma; H Hotta
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

7.  Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation.

Authors:  C M Shih; C M Chen; S Y Chen; Y H Lee
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

8.  High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis.

Authors:  M Giménez-Barcons; S Franco; Y Suárez; X Forns; S Ampurdanès; F Puig-Basagoiti; A Sánchez-Fueyo; J M Barrera; J M Llovet; J Bruix; J M Sánchez-Tapias; J Rodés; J C Saiz
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

9.  Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a.

Authors:  M I Lusida; M Nagano-Fujii; C A Nidom; R Handajani; T Fujita; K Oka; H Hotta
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

10.  Synthesis of a novel hepatitis C virus protein by ribosomal frameshift.

Authors:  Z Xu; J Choi; T S Yen; W Lu; A Strohecker; S Govindarajan; D Chien; M J Selby; J Ou
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

View more
  14 in total

1.  Functional characterization of core genes from patients with acute hepatitis C virus infection.

Authors:  Xi Tang; Jessica Wagoner; Amina Negash; Michael Austin; John McLauchlan; Young S Hahn; Hugo R Rosen; Stephen J Polyak
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

2.  Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.

Authors:  Soo Ryang Kim; Ahmed El-Shamy; Susumu Imoto; Ke Ih Kim; Yoshi-hiro Ide; Lin Deng; Ikuo Shoji; Yasuhito Tanaka; Yutaka Hasegawa; Mitsuhiro Ota; Hak Hotta
Journal:  J Gastroenterol       Date:  2012-03-24       Impact factor: 7.527

3.  Hepatitis C virus Genotype 1a core gene nucleotide patterns associated with hepatocellular carcinoma risk.

Authors:  Brent Korba; Kirti Shetty; Alexei Medvedev; Prasanth Viswanathan; Rency Varghese; Bin Zhou; Rabindra Roy; Kepher Makambi; Habtom Ressom; Christopher A Loffredo
Journal:  J Gen Virol       Date:  2015-07-03       Impact factor: 3.891

4.  The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma.

Authors:  Xiaoan Zhang; Soo Hyung Ryu; Yanjuan Xu; Tamerl Elbaz; Abdel-Rahman N Zekri; Ashraf Omar Abdelaziz; Mohamed Abdel-Hamid; Valerie Thiers; Santiago F Elena; Xiaofeng Fan; Adrian M Di Bisceglie
Journal:  J Clin Virol       Date:  2011-09-17       Impact factor: 3.168

Review 5.  Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma.

Authors:  Virginia Sedeno-Monge; Veronica Vallejo-Ruiz; Francisca Sosa-Jurado; Gerardo Santos-Lopez
Journal:  J Biosci       Date:  2017-09       Impact factor: 1.826

6.  Expression of the novel hepatitis C virus core+1/ARF protein in the context of JFH1-based replicons.

Authors:  Ioly Kotta-Loizou; Ioannis Karakasiliotis; Niki Vassilaki; Panagiotis Sakellariou; Ralf Bartenschlager; Penelope Mavromara
Journal:  J Virol       Date:  2015-02-18       Impact factor: 5.103

Review 7.  Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

Authors:  Maria Victoria Preciado; Pamela Valva; Alejandro Escobar-Gutierrez; Paula Rahal; Karina Ruiz-Tovar; Lilian Yamasaki; Carlos Vazquez-Chacon; Armando Martinez-Guarneros; Juan Carlos Carpio-Pedroza; Salvador Fonseca-Coronado; Mayra Cruz-Rivera
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

8.  Cell-mediated immune responses directed against hepatitis C virus (HCV) alternate reading frame protein (ARFP) are undetectable during acute infection.

Authors:  Christian Drouin; Stéphanie Lamarche; Julie Bruneau; Hugo Soudeyns; Naglaa H Shoukry
Journal:  J Clin Virol       Date:  2009-12-01       Impact factor: 3.168

Review 9.  Production and pathogenicity of hepatitis C virus core gene products.

Authors:  Hui-Chun Li; Hsin-Chieh Ma; Chee-Hing Yang; Shih-Yen Lo
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma.

Authors:  Sarah L Fishman; Stephanie H Factor; Cinzia Balestrieri; Xiaofeng Fan; Adrian M Dibisceglie; Suresh M Desai; Gary Benson; Andrea D Branch
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.